Tier 2 — strong

Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori

Chen XX, Chen YX, Bi HX, Zhao X, Zhang LF, Liu JY, Shi YQ
Journal of digestive diseases 2022 23(10):568-576

Bibliography

PubMed
PMID 36415112
PubMed Central
PMC10107123
DOI
10.1111/1751-2980.13146
Funding
Indexed support: State Key Laboratory of Cancer Biology; National Natural Science Foundation of China. See the publication for grant details.
Competing interests
The authors declared no competing interests in the publication.

Study snapshot

DesignOpen-label randomized noninferiority trial
ModelHuman participants; see population
Sample524 adults; 262 per arm
InterventionBerberine 300 mg three times/day plus amoxicillin/rabeprazole versus bismuth quadruple therapy
Duration14 days
EndpointsEradication or stool-output outcomes; Treatment tolerability; Adherence

What the study showed, in plain terms

Berberine-containing triple therapy met the prespecified noninferiority criterion in this treatment-naive cohort.

Key findings

  • Berberine-containing triple therapy met the prespecified noninferiority criterion in this treatment-naive cohort.

What this study can and cannot tell us

Multidrug, region-specific regimen; noninferiority depends on the chosen margin and does not isolate berberine’s contribution.

Related papers in the corpus

Tier 2
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial
Chen S et al. · Chinese medical journal · 2023
Tier 2
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment
Zhang J et al. · Journal of digestive diseases · 2020
Tier 2
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial
Zhang D et al. · Medicine · 2017
Tier 2
Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae
Rabbani GH et al. · The Journal of infectious diseases · 1987
Tier 2
Clinical trial of berberine in acute watery diarrhoea
Khin-Maung-U et al. · British medical journal (Clinical research ed.) · 1985

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology